Figure 2

Development of centrofacial telangiectasia (TAE) in patients with systemic sclerosis (SSc) treated with bosentan or iloprost over ten months. Patients receiving (a) bosentan (n = 6) developed significantly (P = 0.027) more TAE (TAE before therapy: n = 10.8 ± 9.5; TAE after ten months of therapy: n = 55.2 ± 29.8) as compared to patients receiving (b) iloprost (n = 6; TAE before therapy: n = 18.3 ± 14.5; TAE after ten months of therapy: n = 20.2 ± 15.5; P = 0.420). Values are plotted as individual ratios, including mean ratio values shown by the horizontal bar. Data were evaluated using a Student’s t- test.